Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Primary microcephaly refers to the clinical finding of a head circumference more than than 3 standard deviations (SD) below the age- and sex-related mean, present at birth. Primary microcephaly is a static developmental anomaly, distinguished from secondary microcephaly, which refers to a progressive neurodegenerative condition. Microcephaly is a disorder of fetal brain growth; individuals with microcephaly have small brains and almost always have intellectual disability, although rare individuals with mild microcephaly (-3 SD) and normal intelligence have been reported. Additional clinical features may include short stature or mild seizures. These clinical features include Seckel syndrome, a rare autosomal recessive disorder characterized by intrauterine growth retardation, dwarfism, microcephaly with intellectual disability.
Biomarker and diagnostic research for microcephaly with or without short stature has been reported in the published literature.
No clinical trials have been registered for microcephaly with or without short stature.
202 publications have been identified in PubMed for microcephaly with or without short stature. Kisho has analyzed 131 by research type. Research spans Basic Science / Preclinical (39%), Review / Meta-Analysis (23%), and Case Report / Case Series (17%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 51 | 39% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 9:39 PM UTC
Research summaries |
30 |
23% |
Patient case studies | 22 | 17% |
Disease patterns and progression | 14 | 11% |
Clinical study results | 7 | 5% |
Testing and diagnosis research | 3 | 2% |
New treatment approaches | 3 | 2% |
Other research | 1 | 1% |
González-Blanco A (2026). [PMID: 41820377](https://pubmed.ncbi.nlm.nih.gov/41820377/). *Nat Commun*. [Basic Science / Preclinical]
Fu Q (2026). [PMID: 41986672](https://pubmed.ncbi.nlm.nih.gov/41986672/). *Eur J Pediatr*. [Review / Meta-Analysis]
Xu H (2026). [PMID: 41189326](https://pubmed.ncbi.nlm.nih.gov/41189326/). *HGG Adv*. [Basic Science / Preclinical]
Ribeiro AC (2026). [PMID: 40554621](https://pubmed.ncbi.nlm.nih.gov/40554621/). *J Clin Endocrinol Metab*. [Epidemiology / Natural History]
Niehaus I (2026). [PMID: 41372632](https://pubmed.ncbi.nlm.nih.gov/41372632/). *EMBO Rep*. [Basic Science / Preclinical]
Dauber A (2026). [PMID: 41543979](https://pubmed.ncbi.nlm.nih.gov/41543979/). *Eur J Endocrinol*. [Review / Meta-Analysis]
Thomsen OK (2025). [PMID: 41349537](https://pubmed.ncbi.nlm.nih.gov/41349537/). *Dev Cell*. [Review / Meta-Analysis]
Trigui M (2025). [PMID: 40987814](https://pubmed.ncbi.nlm.nih.gov/40987814/). *Eur J Hum Genet*. [Basic Science / Preclinical]
Kaba I (2025). [PMID: 40326894](https://pubmed.ncbi.nlm.nih.gov/40326894/). *Niger J Clin Pract*. [Epidemiology / Natural History]
Matsuhashi K (2025). [PMID: 40921755](https://pubmed.ncbi.nlm.nih.gov/40921755/). *Nat Commun*. [Case Report / Case Series]